There is increased risk for major gastrointestinal bleeding with edoxaban vs VKA therapy in patients with atrial fibrillation following TAVR.

The global transcatheter heart valve replacement (TAVR) market is estimated to be valued at USD 8.18 billion in 2025 and is projected to reach USD 32.82 billion by 2035, registering a compound annual ...

At Sanford Health in Bismarck, doctors have now performed 500 transcatheter aortic valve replacements, known as TAVR.

The study isn’t intended to sway clinical decision-making, but to make doctors aware of the impact of their choices.